AbbVie, a pharmaceutical leader, overcame patent cliff challenges and has a strong outlook. The company diversified its product lineup and is less reliant on a single medicine. AbbVie aims to expand into oncology and weight loss markets. It remains a top dividend stock with plans for future growth.

Merck faces threats to its HPV vaccine sales and competition for its cancer medicine, Keytruda. However, the company is fighting back with new approvals and pipeline candidates, including vaccines and pulmonary arterial hypertension medicine. Merck is also a solid dividend stock with growth potential.

AbbVie and Merck are two leading pharmaceutical stocks that look reasonably valued and are attractive for investment in 2026. AbbVie has solidified its position post-Humira patent cliff, while Merck is focusing on new approvals and acquisitions to strengthen its portfolio. Both companies are poised for growth despite challenges.

Read more at Yahoo Finance: Here Are 2 Affordable Healthcare Stocks to Buy Heading Into 2026